Development of a Disease Specific Quality of Life Questionnaire for Patients with Graves' Ophthalmopathy: the GO-QOL

Overview

Journal Br J Ophthalmol

Specialty Ophthalmology

Date 1999 Jan 30

PMID 9924370

Citations 92

Authors

C B Terwee

M N Gerding

F W Dekker

M F Prummel

W M Wiersinga

Affiliations

Soon will be listed here.

Abstract

Aim: To develop a reliable and valid disease specific quality of life questionnaire (the GO-QOL) for patients with Graves' ophthalmopathy (GO), that can be used to describe the health related quality of life and changes in health related quality of life over time as a consequence of disease and treatment.

Methods: 70 consecutive GO patients (age > 18 years) who were referred for the first time to the combined outpatient clinic of the orbital centre and the department of endocrinology completed the 16 questions of the GO-QOL. Additional information on general quality of life and disease characteristics was obtained. Construct validity and internal consistency of the disease specific questionnaire was determined, based on principal component analysis, Cronbach alphas and correlations with MOS-24, three subscales of the SIP, demographic, and clinical measures.

Results: The a priori expected subdivision of the questionnaire in two subscales, one measuring the consequences of double vision and decreased visual acuity on visual functioning, and one measuring the psychosocial consequences of a changed appearance, was confirmed in the principal component analysis. Both scales had a good reliability and high face validity. Correlations with other measures supported construct validity. Mean scores (range 0-100) were 54.7 (SD 22.8) for visual functioning and 60.1 (24.8) for appearance (higher score = better health).

Conclusion: The GO-QOL is a promising tool to measure disease specific aspects of quality of life in patients with GO and provides additional information to traditional physiological or biological measures of health status.

Citing Articles

Selenium vs Control for Graves Ophthalmopathy in a Selenium-Sufficient Area: A Randomized Clinical Trial.

Ahn H, Lee M, Jung K, Kim H, Jung E, Chung C JAMA Ophthalmol. 2025; .

PMID: 40014353 PMC: 11869097. DOI: 10.1001/jamaophthalmol.2024.6337.

Nonsurgical management of upper eyelid retraction in thyroid eye disease.

Young S, Kim Y, Woo K Taiwan J Ophthalmol. 2025; 14(4):548-553.

PMID: 39803393 PMC: 11717341. DOI: 10.4103/tjo.TJO-D-23-00043.

Investigating factors influencing quality of life in thyroid eye disease: insight from machine learning approaches.

Zhang H, Wu S, Yang L, Fan C, Chen H, Wang H Eur Thyroid J. 2024; 14(1).

PMID: 39689235 PMC: 11816044. DOI: 10.1530/ETJ-24-0292.

Long-term outcome of Graves' orbitopathy following treatment with sirolimus.

Comi S, Cosentino G, Lanzolla G, Menconi F, Maglionico M, Posarelli C J Endocrinol Invest. 2024; 48(3):607-618.

PMID: 39373962 PMC: 11876206. DOI: 10.1007/s40618-024-02470-8.

Quality of life in patients with Graves' orbitopathy submitted to orbital decompression: comparison between balanced and inferomedial techniques.

Leite C, Pereira T, Chiang J, Moritz R, Goncalves A, Monteiro M Arq Bras Oftalmol. 2024; 87(5):e20230296.

PMID: 39109703 PMC: 11627165. DOI: 10.5935/0004-2749.2023-0296.

References

. Classification of eye changes of Graves' disease. Thyroid. 1992; 2(3):235-6. DOI: 10.1089/thy.1992.2.235. View

Mangione C, Phillips R, Seddon J, Lawrence M, Cook E, Dailey R . Development of the 'Activities of Daily Vision Scale'. A measure of visual functional status. Med Care. 1992; 30(12):1111-26. DOI: 10.1097/00005650-199212000-00004. View

Weetman A . Thyroid-associated eye disease: pathophysiology. Lancet. 1991; 338(8758):25-8. DOI: 10.1016/0140-6736(91)90013-f. View

Prummel M, Mourits M, Berghout A, Krenning E, van der Gaag R, Koornneef L . Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med. 1989; 321(20):1353-9. DOI: 10.1056/NEJM198911163212002. View

Patrick D, Deyo R . Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989; 27(3 Suppl):S217-32. DOI: 10.1097/00005650-198903001-00018. View

Stewart A, Hays R, Ware Jr J . The MOS short-form general health survey. Reliability and validity in a patient population. Med Care. 1988; 26(7):724-35. DOI: 10.1097/00005650-198807000-00007. View

Guyatt G, Bombardier C, Tugwell P . Measuring disease-specific quality of life in clinical trials. CMAJ. 1986; 134(8):889-95. PMC: 1490966. View

WERNER S . Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab. 1977; 44(1):203-4. DOI: 10.1210/jcem-44-1-203. View

Bergner M, Bobbitt R, Carter W, Gilson B . The Sickness Impact Profile: development and final revision of a health status measure. Med Care. 1981; 19(8):787-805. DOI: 10.1097/00005650-198108000-00001. View

10.

Cassard S, Patrick D, Damiano A, Legro M, Tielsch J, Diener-West M . Reproducibility and responsiveness of the VF-14. An index of functional impairment in patients with cataracts. Arch Ophthalmol. 1995; 113(12):1508-13. DOI: 10.1001/archopht.1995.01100120038005. View

11.

Ellwein L, Fletcher A, Negrel A, Thulasiraj R . Quality of life assessment in blindness prevention interventions. Int Ophthalmol. 1994; 18(5):263-8. DOI: 10.1007/BF00917828. View

12.

Damiano A, Steinberg E, Cassard S, Bass E, Diener-West M, Legro M . Comparison of generic versus disease-specific measures of functional impairment in patients with cataract. Med Care. 1995; 33(4 Suppl):AS120-30. View

13.

Mangione C, Phillips R, Lawrence M, Seddon J, Orav E, Goldman L . Improved visual function and attenuation of declines in health-related quality of life after cataract extraction. Arch Ophthalmol. 1994; 112(11):1419-25. DOI: 10.1001/archopht.1994.01090230033017. View

14.

Wilson I, Cleary P . Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995; 273(1):59-65. View

15.

Prummel M, Mourits M, Blank L, Berghout A, Koornneef L, Wiersinga W . Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet. 1993; 342(8877):949-54. DOI: 10.1016/0140-6736(93)92001-a. View

16.

Lyons C, Rootman J . Orbital decompression for disfiguring exophthalmos in thyroid orbitopathy. Ophthalmology. 1994; 101(2):223-30. DOI: 10.1016/s0161-6420(94)31343-1. View

17.

Burch H, Wartofsky L . Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev. 1993; 14(6):747-93. DOI: 10.1210/edrv-14-6-747. View

18.

Salive M, Guralnik J, Glynn R, Christen W, Wallace R, OSTFELD A . Association of visual impairment with mobility and physical function. J Am Geriatr Soc. 1994; 42(3):287-92. DOI: 10.1111/j.1532-5415.1994.tb01753.x. View

19.

Scott I, Schein O, West S, Bandeen-Roche K, Enger C, Folstein M . Functional status and quality of life measurement among ophthalmic patients. Arch Ophthalmol. 1994; 112(3):329-35. DOI: 10.1001/archopht.1994.01090150059023. View

20.

Steinberg E, Tielsch J, Schein O, Javitt J, Sharkey P, Cassard S . The VF-14. An index of functional impairment in patients with cataract. Arch Ophthalmol. 1994; 112(5):630-8. DOI: 10.1001/archopht.1994.01090170074026. View